594 related articles for article (PubMed ID: 26648552)
1. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
3. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
4. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
Nagata H; Hatano E; Tada M; Murata M; Kitamura K; Asechi H; Narita M; Yanagida A; Tamaki N; Yagi S; Ikai I; Matsuzaki K; Uemoto S
Hepatology; 2009 Jun; 49(6):1944-53. PubMed ID: 19418558
[TBL] [Abstract][Full Text] [Related]
6. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
[TBL] [Abstract][Full Text] [Related]
7. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.
Yu G; Chen X; Chen S; Ye W; Hou K; Liang M
J Transl Med; 2016 May; 14(1):122. PubMed ID: 27150195
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus X protein amplifies TGF-β promotion on HCC motility through down-regulating PPM1a.
Liu Y; Xu Y; Ma H; Wang B; Xu L; Zhang H; Song X; Gao L; Liang X; Ma C
Oncotarget; 2016 May; 7(22):33125-35. PubMed ID: 27121309
[TBL] [Abstract][Full Text] [Related]
9. HBX protein promotes LASP-1 expression through activation of c-Jun in human hepatoma cells.
You H; Kong F; Zhou K; Wei X; Hu L; Hu W; Luo W; Kou Y; Liu X; Chen X; Zheng K; Tang R
J Cell Physiol; 2018 Sep; 233(9):7279-7291. PubMed ID: 29600594
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Wang SH; Yeh SH; Shiau CW; Chen KF; Lin WH; Tsai TF; Teng YC; Chen DS; Chen PJ
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26206949
[TBL] [Abstract][Full Text] [Related]
11. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma.
Lee WP; Lan KH; Li CP; Chao Y; Lin HC; Lee SD
Biochim Biophys Acta; 2016 Apr; 1862(4):837-849. PubMed ID: 26791804
[TBL] [Abstract][Full Text] [Related]
13. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
Matsuzaki K
Histol Histopathol; 2006 Jun; 21(6):645-62. PubMed ID: 16528675
[TBL] [Abstract][Full Text] [Related]
14. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
Li Q; Liu G; Shao D; Wang J; Yuan H; Chen T; Zhai R; Ni W; Tai G
Int J Biochem Cell Biol; 2015 Feb; 59():116-25. PubMed ID: 25526895
[TBL] [Abstract][Full Text] [Related]
15. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
16. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.
Pang R; Lee TK; Poon RT; Fan ST; Wong KB; Kwong YL; Tse E
Gastroenterology; 2007 Mar; 132(3):1088-103. PubMed ID: 17383430
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus X protein activates Notch signaling by its effects on Notch1 and Notch4 in human hepatocellular carcinoma.
Gao J; Xiong Y; Wang Y; Wang Y; Zheng G; Xu H
Int J Oncol; 2016 Jan; 48(1):329-37. PubMed ID: 26530164
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma.
Kew MC
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():144-52. PubMed ID: 21199526
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus induces hypoxia-inducible factor-2α expression through hepatitis B virus X protein.
Hu JL; Liu LP; Yang SL; Fang X; Wen L; Ren QG; Yu C
Oncol Rep; 2016 Mar; 35(3):1443-8. PubMed ID: 26647960
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin.
Li J; Dai X; Zhang H; Zhang W; Sun S; Gao T; Kou Z; Yu H; Guo Y; Du L; Jiang S; Zhang J; Zhou Y
Oncotarget; 2015 Oct; 6(30):29196-208. PubMed ID: 26470691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
